Background
Cristina Adriana Popa
To INFINITI and Beyond: SGLT2 Inhibitors in ...

This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients
Background
Cristina Adriana Popa
POTCAST- K+ Pop and Arrhythmia Drop

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

POTCAST- K+ Pop and Arrhythmia Drop
Background
Brian Rifkin
A VALIANT effort to combat complement disorders ...

This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.

A VALIANT effort to combat complement disorders with pegcetacoplan
news
Cristina Adriana Popa
Top Stories in Nephrology 2025

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

Top Stories in Nephrology 2025
Background
Brian Rifkin
Dialyze Less, Recover More? AKI’s Chance to Get ...

This week, we will discuss whether less is more when it comes to discontinuing dialysis in patients with AKI and a chance to recover.

Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D

positive

VALIANT: The Visual Abstract

The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.

Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.

ORIGIN-3: El Resumen Visual

ORIGIN-3 ha llegado a NephJC con atacicept en NIgA.
Un paso sólido hacia una terapia dirigida anti BAFF/APRIL, que aborda la fisiopatología desde su origen. ¡Las señales tempranas son prometedoras!

Revisa el resumen visual realizado por Clemens Weber

,

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

,
Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

Potassium Rollercoaster Heartbreak

Potassium Rollercoaster Heartbreak

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

HDF vs HD: Need for CONVINCE-ing Evidence

HDF vs HD: Need for CONVINCE-ing Evidence

This week, we will discuss CONVINCE, a randomized controlled trial, about the long-lasting battle between hemodialysis and hemodiafiltration. Will it convince the unconvinced, or will it diffuse even more uncertainty into community?